Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV‐1 reservoirs: results from a multicentre randomized clinical study

@article{Routy2012ValproicAI,
  title={Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV‐1 reservoirs: results from a multicentre randomized clinical study},
  author={Jean-Pierre Routy and C{\'e}cile L Tremblay and Jonathan B. Angel and Benoit Trottier and Danielle Rouleau and Jean Guy Baril and M Harris and Sylvie Trottier and Joel Singer and Nicolas Chomont and R P S{\'e}kaly and Mohamed-Rachid Boulassel},
  journal={HIV Medicine},
  year={2012},
  volume={13}
}
Conflicting results have been reported regarding the ability of valproic acid (VPA) to reduce the size of HIV reservoirs in patients receiving suppressive highly active antiretroviral therapy (HAART). In a randomized multicentre, cross‐over study, we assessed whether adding VPA to stable HAART could potentially reduce the size of the latent viral reservoir in CD4 T cells of chronically infected patients. 
Repurposing medications for use in treating HIV infection: A focus on valproic acid as a latency‐reversing agent
TLDR
The purpose of this review was to critically evaluate the available literature on innovative use of valproic acid (VPA) for the agent's therapeutic effects on reversing latent human immunodeficiency virus (HIV) reservoirs.
Design and Implementation of a Randomized Crossover Study of Valproic Acid and Antiretroviral Therapy to Reduce the HIV Reservoir
TLDR
Despite the absence of demonstrable impact of VPA on reservoir size, such crossover study design should be considered in the early stage testing of novel HIV therapeutics targeted to reduce reservoir size or eradicate HIV.
HIV-1 Eradication: Early Trials (and Tribulations).
TLDR
Recent advances in pharmacologically based 'shock and kill' HIV-1 eradication strategies are reviewed, including comparative analysis of early clinical trials.
Safety of valproic acid in patients with chronic obstructive pulmonary disease: a population-based cohort study
TLDR
The risk of COPD exacerbation in older patients with COPD commencing treatment with either valproic acid or phenytoin, an anticonvulsant that does not affect HDAC is compared.
Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial.
TLDR
A multifaceted approach that includes stronger activators of HIV expression and novel immune modulators will probably be needed to reduce the latent HIV reservoir and allow for long-term control in patients off antiretroviral therapy.
Eliminating the latent HIV reservoir by reactivation strategies
TLDR
Compounds that are currently being or soon to be tested in clinical trials are emphasized and will provide important clues as to whether or not reactivating strategies could become significant components of a cure for HIV.
Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents
TLDR
A summary of ongoing clinical trials of HIV LRAs and immunomodulatory molecules is provided, and it highlights challenges in the comparison and interpretation of the expected trial results.
Reversal of Latency as Part of a Cure for HIV-1.
Here, the use of pharmacological agents to reverse HIV-1 latency will be explored as a therapeutic strategy towards a cure. However, while clinical trials of latency-reversing agents LRAs) have
Comparison of HDAC inhibitors in clinical development Effect on HIV production in latently infected cells and T-cell activation
The inability of highly active antiretroviral treatment (HAART) to eradicate HIV-infection has renewed interest in the search for a cure. The primary barrier preventing eradication of HIVinfection by
The Effect of Therapeutic HIV Vaccination With ALVAC-HIV With or Without Remune on the Size of the Viral Reservoir (A CTN 173 Substudy)
TLDR
Despite evidence that ALVAC-HIV ± Remune was associated with a trend toward a delay in viral rebound and a smaller decrease in CD4 T-cell counts following antiretroviral therapy interruption, ALVAT did not influence the size of the viral reservoir.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 23 REFERENCES
The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial
In a double-blind trial, Rajesh Gandhi and colleagues detect no significant reduction in viral load after people with low-level HIV viremia added an integrase inhibitor to their treatment regimen.
Stability of the latent reservoir for HIV-1 in patients receiving valproic acid.
TLDR
It is concluded that the clinical use of VA has no ancillary effect on the decay of the latent reservoir for HIV-1 and the eventual eradication of the infection.
Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir
TLDR
Long-term valproic acid therapy seems to be insufficient to reduce the size of the HIV-1 reservoir, and total and integrated HIV DNA were logarithmically more abundant than cells carrying replication-competent virus.
Antiretroviral Intensification and Valproic Acid Lack Sustained Effect on Residual HIV-1 Viremia or Resting CD4+ Cell Infection
TLDR
The prospective addition of Vpa and RAL, VPA and ENF, or ENF failed to progressively reduce the frequency of RCI, or ablate intermittent and low-level viremia.
No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy.
TLDR
The stability of the latent reservoir despite intensive therapy suggests that new strategies are needed to eradicate HIV-1 from this reservoir.
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells
TLDR
The prospective addition of valproic acid to stable antiretroviral therapy reduced the frequency of resting CD4+ T-cell infection in a minority of volunteers.
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.
TLDR
In a study of 22 patients successfully treated with HAART for up to 30 months, replication-competent virus was routinely recovered from resting CD4+ T lymphocytes, and generally did not show mutations associated with resistance to the relevant antiretroviral drugs.
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells
TLDR
It is shown that even in treated patients who have had no detectable viremia for as long as 7 years, the reservoir decays so slowly that eradication is unlikely.
Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies.
TLDR
The administration of deacetylase inhibitor(s) together with continuous HAART is proposed as a new potential therapeutic perspective to decrease the pool of latent HIV reservoirs by forcing viral expression.
Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs
TLDR
This Review analyses the molecular mechanisms that are necessary for the establishment of HIV-1 latency and their relationships with different cellular and anatomical reservoirs, and discusses the current treatment strategies for targeting viral persistence in reservoirs, their main limitations and future perspectives.
...
1
2
3
...